CIAN HEALTHCARE LTD.

NSE : NABSE : 542678ISIN CODE : INE05BN01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE21.500 (0 %)
PREV CLOSE ( ) 21.50
OPEN PRICE ( ) 21.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4000
TODAY'S LOW / HIGH ( )21.50 21.50
52 WK LOW / HIGH ( ) 16.0541.1
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2023Mar2022Mar2021Mar2020
Profit Before Tax20.30-55.340.53-37.88
Adjustment100.9496.66108.32113.99
Changes In working Capital-72.8344.46-49.52-149.18
Cash Flow after changes in Working Capital48.4185.7859.33-73.07
Cash Flow from Operating Activities48.4185.7859.33-73.07
Cash Flow from Investing Activities25.5513.9627.14-274.41
Cash Flow from Financing Activities-74.08-109.57-97.75357.80
Net Cash Inflow / Outflow-0.12-9.83-11.2910.31
Opening Cash & Cash Equivalents13.4223.2534.5424.22
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANA
Effect of Foreign Exchange FluctuationsNANANANA
Closing Cash & Cash Equivalent13.3013.4223.2534.54

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.